This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Comorbid Anxiety and Depression.

Mark H. Pollack, MD

Published: November 15, 2005

Article Abstract

Anxiety and depressive disorders often occur as comorbid illnesses and share many commonsymptoms. Risk factors for these disorders most likely include interactions of environmental and geneticfactors. The presence of comorbid anxiety and depression adversely affects clinical and treatmentoutcomes. Selective serotonin reuptake inhibitors are usually considered first-line treatment forpatients with these disorders, although alternative antidepressants or additional therapies are oftennecessary. Studies suggest that benzodiazepines, anticonvulsants, and atypical antipsychotics may beeffective as augmentation therapy to optimize outcome, with buspirone and beta-blockers usefulin some patients as well. Cognitive-behavioral therapy is also an effective therapeutic alternative foraffected patients.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 66

Quick Links: Comorbidity , Medical

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...